arXiv subjects

Micheal O'Riordain

Publications and source records attributed to Micheal O'Riordain.

2 recordsLinked to original sources

arXiv2026

Multi-center Medical Data Mining with FL-Net - A One-stop Shop for Federated Learning

Federated learning enables collaborative training without sharing patient-level data, but most studies remain simulations. Based on five requirements derived from the literature, we analyzed 14 FL frameworks and found that none fully satisfied these requirements. We present FL-Net, a novel federated clinical research framework to fulfill all requirements. It integrates modular data harmonization, data discovery, disclosure control, securely built versioned FL-Net-Tools and containerized federated workflow execution into a persistent network. It enables the re-use of harmonized data and workflows across studies. FL-Net's end-to-end capabilities were evaluated through harmonization, cross-study patient discovery across MIMIC and US-130, and reproducible, audited federated workflows with up to 50 concurrent clients. FL-Net is being developed within the dAIbetes and Microb-AI-ome EU projects and will cover over 800,000 patients across 10 hospitals in 9 countries covering longitudinal and single point in time data, FL-Net provides a practical foundation for interoperable, reproducible, and privacy-preserving multicenter clinical research.

cs.LG↗

arXiv2025

Cancer model with moving extinction threshold reproduces real cancer data

We propose a simple dynamic model of cancer development that captures carcinogenesis and subsequent cancer progression. A central idea of the model is to include the immune system as an extinction threshold, similar to the strong Allee effect in population biology. We first identify the limitations of commonly used Allee effect models in reproducing typical cancer progression. We then address these limitations by deriving a new model that incorporates: (i) random mutations of stem cells at a rate that increases with age and (ii) immune response whose strength may also vary over time. Our model accurately reproduces a wide range of real-world cancer data: the typical age-specific cumulative risk of most human cancers, the progression of breast cancer in mice, and the unusual age-specific cumulative risk of breast cancer in women. In the last case, we use a moving extinction threshold to reflect the different immune response at different phases of the menstrual cycle and menopausal treatment. This provides new insights into the effects of hormone replacement therapy and menstrual cycle length. This moving threshold approach can be applied to a variety of other cancer scenarios where the immune response or other important factors may vary over time.

q-bio.QM↗